Company ProfilePremium

Aprogen pharmaceuticals,Inc.

Company Profile Analysis

Ticker: 003060.KS주식회사 에이프로젠바이오로직스

ESOMAR 23 Corporate BadgeISO Certifications Badge
Aprogen pharmaceuticals,Inc. - Company showcase

Year Founded & Workforce

1960

262 Employees

Aprogen pharmaceuticals,Inc. logo

Aprogen pharmaceuticals,Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Aprogen pharmaceuticals,Inc. Overview

Aprogen Biologics is a loss-making, majority-controlled Korean pharmaceutical and biologics manufacturer. It combines a 65-year-old domestic ethical-drug business, inherited from Kunpoong and Schnell, with one of Korea's largest perfusion-based antibody plants in Osong. Group materials put the plant's investment at about KRW 600 bn and its capacity at roughly 3,000 kg of antibody a year. Within the Aprogen group, the company is the designated manufacturer for biosimilars and novel biologics developed by its parent, Aprogen Inc. These include the infliximab biosimilar GS071, the trastuzumab biosimilar AP063, and the adalimumab and rituximab candidates AP096 and AP056. In Q1 2026, however, Osong recorded zero litres of biologic output, and the company has posted operating losses of KRW 52.8–60.4 bn a year since FY2023. A newly reported semiconductor segment is currently its only profitable division. The investment case rests on AP063 approvals following FDA and EMA regulatory feedback that waives Phase 3, on the first commercial CDMO contracts, and on how long the parent can continue funding the company.


What the company does

Aprogen Biologics operates three reportable activities, plus residual "other" items.

  1. Pharmaceutical business (제약사업부문). This is the legacy Kunpoong/Schnell business: manufacture and domestic sale of prescription and generic medicines. Third-party profiles describe the line-up as including amino-acid infusion products and antibiotics (Dealroom). Asia Economy (June 2020) described the predecessor, Aprogen Pharmaceuticals, as an antibiotics-focused drug maker. Recruitment postings (Catch, 2026) refer to a Hwaseong plant with a tablet-coating production line, a regulatory-affairs (RA) development team, and a "CSO support team." The CSO reference indicates the company uses contract sales organisations for domestic marketing. In Q2 2026 the segment generated 62% of revenue (Butler).

  2. Bio business (바이오사업부문). This is the Osong cGMP biologics plant acquired through the December 2022 merger with the former unlisted Aprogen Biologics. The plant was completed in January 2020. It holds the following capacity:

    • Drug substance: four 2,500 L bioreactors (2,000 L working volume) and two 250 L bioreactors, designed for perfusion culture.

    • Drug product: fill-finish lines for lyophilised vials, liquid vials, prefilled syringes and auto-injectors. The segment's intended revenue streams are (a) manufacturing the Aprogen group's biosimilars and (b) third-party CMO/CDMO work. In Q2 2026 the segment contributed only 3% of revenue (Butler) and generated nearly all of the operating loss: about KRW 13.2 bn in Q1 2026 and about KRW 30.5 bn in H1 2026 (IB Tomato).

  3. Semiconductor business (반도체사업부문). This segment appears in 2026 segment reporting. It contributed 33% of Q2 2026 revenue and an operating profit of about KRW 2.25 bn in H1 2026 (Butler; IB Tomato). Its origin, legal form and products could not be confirmed in sources reviewed. Elsewhere in the group, semiconductor-equipment parts are made by N2Tech (엔투텍, vacuum gate valves), which group-level profiles associate with Aprogen Inc. (Valueline).

Business and revenue model

Revenue streamTypeStatus (2026)
Domestic prescription / generic drugsProduct salesCore revenue; segment profitable in Q1 2026 (KRW 1.8 bn operating profit), loss-making in H1 2026 (about –KRW 3.3 bn)
Biosimilar manufacturing for the Aprogen groupContract manufacturing / intra-group supplyNo commercial output in Q1 2026 (0 L produced)
Third-party CMO/CDMOServiceTrial fill-finish run for a "Company C" completed (Hankyung, January 2025); audits by a European "Company O"; no commercial contract confirmed in sources reviewed
Semiconductor productsProduct sales33% of Q2 2026 revenue; only profitable segment in H1 2026
Related-party servicesServiceAprogen Inc. recorded about KRW 1.9 bn of service transactions with the company between March and August 2026 (IB Tomato)

Licensing income does not appear to be booked at Aprogen Biologics. Biosimilar IP and out-licensing rights sit with Aprogen Inc. Partner Nichi-Iko paid upfront fees of KRW 10 bn each for GS071, AP063 and AP056 to Aprogen, not to the listed predecessor (Medical Times, March 2016). Under the 2020 group restructuring plan, the listed predecessor held domestic biosimilar sales rights. Asia Economy also reported that a profit-allocation agreement on production from the Osong facility was planned. Its current terms are not publicly disclosed.

Value-chain position, customers and end-markets

Value-chain position: Downstream manufacturer within a vertically split group. In the 2020 design, Aprogen Inc. does R&D, the listed predecessor does sales, and Aprogen Biologics does production. After the December 2022 merger, the listed entity carries both the sales (pharma) and production (bio) roles.

Customers: - Pharma: hospitals, clinics and pharmacies in Korea, served directly and through CSOs and distributors.

  • Bio: Aprogen Inc. (captive) and prospective third-party biopharma CDMO clients in Korea, Japan and Europe.

  • Semiconductor: not disclosed.

End-markets: Korean prescription-drug market; global biosimilar supply (indirectly, through Aprogen's partners such as Nichi-Iko in Japan); global biologics CDMO; semiconductor supply chain (details undisclosed).

Company self-description vs. independent characterisation

The company's English-language self-description in its latest annual report was not accessible in sources reviewed. Group investor materials (Aprogen IR, June 2025) present Osong as a facility with globally unmatched manufacturing cost. They state that a single 2,500 L perfusion bioreactor batch (about 200 kg before purification for AP096) equals the output of four to six 15,000 L fed-batch bioreactors at competitors. The group targets a "Global Top Tier CDMO" position and expected a turnaround around 2027.

Independent characterisation. Aprogen Biologics is a sub-scale domestic generic-drug company carrying a large, idle biologics asset. Its losses are structural. Fixed costs at Osong, including about KRW 3.1 bn of quarterly depreciation on KRW 152.8 bn of machinery (Q1 2026), are not covered by output, and the plant's utilisation depends on regulatory milestones of the parent's biosimilars. Since 2024 the company has relied on related-party funding: placements to the parent, convertible bonds bought by affiliates, and parent loans. It has also pledged its own core real estate as collateral for the parent's borrowings. The semiconductor segment adds diversification but has no stated strategic link to the biologics business.

Strategy

Stated strategy (group investor materials, June 2025; paraphrased)

The group describes its ambition as becoming a company with world-class commercial competitiveness from R&D through manufacturing. It identifies four vectors:

  1. Accelerate biosimilar development and approvals.

  2. Co-develop or out-license new-drug projects.

  3. Open global sales channels.

  4. Fully launch the CDMO business.

The group also claims a cost advantage: perfusion culture combined with high-yield cell lines would let it set prices well below those of fed-batch competitors.

Three business pillars and 13 projects (Aprogen IR, June 2025)

PillarProjectsStatus claimed (Jun 2025)
Biosimilar CDMO (contract development and manufacturing)61 molecule contracted (DS and DP); 3 under negotiation; bispecific manufacturing platform; out-licensing of an acute-leukaemia ADC antibody
Biosimilar licensing (rights) business3AP063 Phase 3; AP096 and AP056 clinical material completed
Novel biologics41 molecule preclinical completed (AP209); 2 in preclinical; 1 in optimisation

The group expected a turnaround around 2027.

Initiatives in the last 24 months

InitiativeDateDescriptionMeasurable target
CDMO commercialisation drive2024–2025Dedicated Japan and Europe CDMO sales organisation; marketing at BIO-Europe and BIO International; Biosecure Act positioningFirst commercial contract expected "within 1–2 months" as of January 2025; not confirmed
Osong expansion designBy Jan 2025Production building designed for 1.5× capacityConstruction conditional on customer demand
AP063 regulatory pivotNov 2025–May 2026Global Phase 3 redesigned to quality and comparative-PK focus; FDA pre-BLA feedback that Phase 3 is not requiredAbout KRW 130 bn development-cost saving (Aprogen claim); BLA after PPQ
Balance-sheet repair2024–202610:1 consolidation (2024) and 15:1 capital reduction (2026) to cover accumulated deficit; avoid KRX penny-stock delisting rulesKeep price above KRW 1,000 and market cap above the KOSPI threshold
Unspecified acquisitionSep 2026KRW 20 bn raised for acquiring securities of an undetermined companyNo target named
Treasury deploymentSep 2026KRW 29.1 bn one-year loan to 아인스팩 at 4.6%Not stated

ESG or sustainability commitments, and cost programmes with numeric targets: none publicly disclosed in sources reviewed.

Medium-term financial guidance: none issued by Aprogen Biologics. In 2020 the group projected revenue above KRW 1 trillion by 2026 (Asia Economy, Apr 2020). Actual group revenue in FY2025 was KRW 118.0 bn at the parent level.

Products & Services

Bio segment — Osong manufacturing services

OfferingDescription / specificationsTarget customerYearPricing
Drug-substance manufacturing (perfusion)4 × 2,500 L (2,000 L working) and 2 × 250 L (200 L working) bioreactors; 4 purification lines. Group states about 125,000 L harvested per batch, about 2.8 million L of culture fluid per year, and 3,000 kg of antibody per yearAprogen group; third-party biopharmaPlant completed Jan 2020—
Drug-substance manufacturing (fed-batch mode)Same bioreactors operated fed-batch; about 300,000 L of culture fluid per year (Asia Economy, Mar 2023)Third-party CDMO clients using conventional processesAvailable since 2020—
Drug product: lyophilised vialsIMA Life equipment; 6.4 million vials per year (Aprogen IR, Jun 2025)Group and third parties2,020—
Drug product: liquid vialsBosch equipment. Capacity stated as 60 million vials per year (Aprogen IR, Jun 2025) but 15 million per year in March 2023 company statements (Asia Economy); the discrepancy is unresolvedGroup and third parties2,020—
Drug product: prefilled syringesOptima equipment; 80 million PFS per yearGroup and third parties2,020—
Auto-injector assembly and secondary packagingAuto-injector assembler, labellers, cartoner, case packer, palletiserGroup and third parties2,020—
Warehousing and QC supportAutomated warehouse (720 cells at 2–8°C; 2,040 cells at 15–25°C); 2 LN2 tanks for cell banks (18,200 × 2 ml vials each); 7 deep freezers; SCADA, LIMS, EDMS, EMS/BMS systemsGroup and third parties2,020—

Bio segment — products manufactured (or to be manufactured) for the Aprogen group

ProductReference product / indicationStatus (latest)Osong role
GS071Remicade (infliximab) biosimilar; autoimmune diseaseApproved in Japan (2017), marketed there through Nichi-Iko; US Phase 3 completed 2019–2020; global rights licensed to Nichi-Iko (2014)Commercial batch production began 2021
AP063Herceptin (trastuzumab) biosimilar; HER2+ breast cancerGlobal Phase 3 started 2023 (19 countries, 720 patients) and later terminated early or redesigned. EMA scientific advice and FDA pre-BLA feedback (8 May 2026) indicate approval may proceed without confirmatory Phase 3. PPQ batches are the next step.Clinical supply produced; PPQ and commercial supply planned. Group claims 92 kg per batch and 736 kg per year (8 batches), equal to about 40% of global consumption
AP096Humira (adalimumab) biosimilar; arthritis and Crohn'sClinical material produced (pre-approval run in November 2024 harvested 201.5 kg HCCF); preparing for clinicGroup claims 156 kg per batch and 1,248 kg per year
AP056Rituxan (rituximab) biosimilar; haematological cancers and autoimmune diseaseClinical material production completed (IR, Jun 2025); ex-Korea rights licensed to Nichi-Iko (2016)Group claims 102 kg per batch and 714 kg per year
AP209Dual-receptor-Fc fusion protein; osteoarthritisKorean clinical trial approved for 46 patients (2026); IRB filing at Kyung Hee University Hospital (August 2026)Clinical drug substance produced at Osong
Parkinson's candidate ("substance K")Neurodegeneration; co-development with Prof. Chung Jong-kyung (Seoul National University)Preclinical; 3 patents in-licensedOsong to manufacture clinical drug (Hankyung, Jan 2025)

These assets are developed and owned by Aprogen Inc. Aprogen Biologics' role is manufacturing, and historically, domestic distribution rights.

Note: IB Tomato (May 2026) described GS071 as a rituximab biosimilar and AP056 as a trastuzumab biosimilar. That conflicts with the company's own investor materials, which identify GS071 as infliximab, AP063 as trastuzumab and AP056 as rituximab.

Pharmaceutical segment

Product lineDescriptionTarget customerNotes
Amino-acid infusion productsParenteral nutritionHospitalsThird-party description (Dealroom); brand names not disclosed in sources reviewed
AntibioticsAnti-infectivesHospitals and clinicsAsia Economy (Jun 2020) described the company as antibiotic-focused; brands not disclosed
Oral solid dosage genericsCoated tablets made at the Hwaseong plantClinics and pharmaciesInferred from recruitment postings (Catch, 2026); product names not disclosed
Historical portfolio (Kunpoong era)Injectables, IV fluids, syrups, oral solidsDomesticeToday (Feb 2010)
Raloxifene (COVID-19 repurposing study, 2020)Investigator-led trial at Ajou University Medical Center——

Product-level revenue, pricing and launch years for pharmaceutical products are not publicly disclosed in sources reviewed.

Semiconductor segment

Products, customers and specifications are not publicly disclosed in sources reviewed.

Financial Narrative

Income statement (consolidated, DART basis via Butler)

Sources: Butler (revenue, operating income, net income FY2021–FY2025). Margins and growth rates are calculated from those figures. Butler reports FY2025 growth as +8.7% and the operating-loss change as –14.3%, based on unrounded figures.

Revenue CAGR FY2021–FY2025: about 6.7% a year (KRW 56.5 bn to KRW 73.2 bn, calculated).

Additional data points:

  • H1 2026: revenue KRW 44.7 bn; operating loss KRW 31.1 bn (IB Tomato, Sep 2026).

  • TTM to mid-2026: revenue about KRW 86.2 bn; EBITDA about –KRW 39.4 bn (MarketInOut, Sep 2026).

  • TTM EPS: –KRW 5,853 (Investing.com, on a post-consolidation share basis) and –KRW 5,872 (MarketInOut).

  • Dividends: none currently (Paasa). The accumulated deficit (–KRW 413.9 bn at Q1 2026) rules out legal dividend capacity.

Commentary.

FY2021–FY2022 (pre-merger): The listed company was a small domestic drug maker. Revenue was KRW 56.5–65.2 bn and operating losses were modest (KRW 3.8–5.4 bn). Net income was positive (KRW 9.2 bn and KRW 5.6 bn), so non-operating gains must have exceeded operating losses. The nature of those gains (for example, valuation gains or interest income) is not disclosed in sources reviewed.

FY2023 (first full year with Osong): Revenue rose 34.0% to KRW 87.4 bn, but the operating loss grew roughly tenfold to KRW 57.5 bn (Asia Economy, Mar 2024). Asia Economy attributed the persistent loss to fixed costs, including SG&A, that revenue could not absorb. The net loss of KRW 115.3 bn implies about KRW 58 bn of non-operating charges (interest, CB-related valuation and/or impairments; breakdown not disclosed).

FY2024: Revenue fell 22.9% to KRW 67.4 bn. The reasons are not disclosed in sources reviewed. Contributing factors could include intra-group supply timing or pharma volumes. The operating loss narrowed slightly to KRW 52.8 bn, and the net loss was KRW 105.0 bn.

FY2025: Revenue recovered 8.6% to KRW 73.2 bn, but the operating loss widened to KRW 60.4 bn. The net loss rose to KRW 168.3 bn, the largest in the five-year window. The roughly KRW 108 bn gap between operating and net loss points to heavy financial or other expenses. Likely components are CB interest and derivative valuation, impairments, or losses on related-party investments; the breakdown is not publicly disclosed in sources reviewed.

2026 run-rate: The H1 2026 operating loss (KRW 31.1 bn) annualises to about KRW 62 bn, so FY2023–FY2025 loss levels are continuing. The bio segment accounts for virtually all of the loss.

Balance sheet (point-in-time data; full 5-year series not publicly accessible in sources reviewed)

Sources: Hankyung (Jan 2024) for September 2023; Aprogen IR (Jun 2025) for March 2025 total assets; IB Tomato (May 2026) for Q1 2026.

Cash and equivalents, gross debt by maturity, net debt, goodwill and intangibles, and working capital for FY2021–FY2025 are not publicly disclosed in sources reviewed. MarketInOut reports debt-to-equity of 1.09 (September 2026).

Commentary.

Equity erosion: Equity roughly halved from KRW 541.4 bn (September 2023) to KRW 272.8 bn (Q1 2026), despite more than KRW 100 bn of new equity raised in 2024.

Deficit relief: The 2026 capital reduction converted about KRW 92.6 bn of share capital into deficit relief, a book entry that does not affect total equity.

Impairment risk: The large machinery balance (KRW 152.8 bn) on a plant that produced nothing in Q1 2026 creates material impairment risk under K-IFRS 1036, as IB Tomato noted.

Encumbered assets: About KRW 81 bn of collateral has been pledged over Osong real estate for the parent's debts. This reduces the company's own borrowing capacity and creates contingent exposure to the parent's credit.

Cash flow

Operating cash flow, capex, free cash flow, dividends paid and buybacks for FY2021–FY2025 are not publicly disclosed in sources reviewed. Funding activity, however, shows the company has depended on external financing:

The 18th-series CB was raised to repay the 17th-series CB issued in March 2025.

Uses of funds:

2024 offering: debt repayment (KRW 30.9 bn of the planned amount), Osong operating costs and equipment upgrades, PPQ test production for AP063 and AP096, and repayment of parent loans (Hankyung; Asia Economy).

September 2026 placement: "acquisition of securities of another company," with counterparty, target and price basis all left undetermined at filing.

September 2026 loan: the company lent KRW 29.1 bn to 아인스팩 for one year at 4.6%. It described the loan as strategic fund management for financial-structure improvement (Dealsite, 23 Sep 2026).

Ratios (latest available; aggregator TTM data)

Current ratio, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle cannot be computed from verified data and are not publicly disclosed in sources reviewed. Net debt/EBITDA and interest coverage are economically meaningless given negative EBITDA.

Parent context: Aprogen Inc. (007460) consolidated, which includes Aprogen Biologics

Sources: Aprogen IR (June 2025) for FY2021–FY2024; IB Tomato (Sep 2026) for FY2025 revenue and operating loss.

The parent's own persistent losses limit how long it can keep funding the subsidiary. The parent itself issued a KRW 20 bn CB in September 2026 to fund its subscription to Aprogen Biologics' placement.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Revenue

SegmentContentsProducts / servicesQ2 2026 revenue share (%)Q1 2026 operating income (KRW Bn)H1 2026 operating income (KRW Bn)

Pharmaceuticals (제약사업부문)

Legacy Kunpoong/Schnell business; Hwaseong plant

Prescription and generic drugs, reportedly including amino-acid infusions and antibiotics

621.8-3.3

Bio (바이오사업부문)

Osong cGMP biologics plant

Biosimilar drug substance and drug product manufacturing; CMO/CDMO

3-13.2-30.5

Semiconductor (반도체사업부문)

——33—2.25

Other

——1——

Total company

——100-13.6-31.1

“—” = not publicly disclosed.

Segment revenue (KRW Bn)

Segment revenue (KRW Bn)FY2023FY2024FY2025

Total company

87.467.473.2

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

56.565.287.467.473.2

Revenue growth YoY (%)

—15.434.0-22.98.6

Operating income (KRW Bn)

-3.8-5.4-57.5-52.8-60.4

Operating margin (%)

-6.7-8.3-65.8-78.3-82.5

Net income (KRW Bn)

9.25.6-115.3-105.0-168.3

Net margin (%)

16.38.6-131.9-155.8-229.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet

MetricSep2023Mar2025Mar2026

Total assets (KRW Bn)

744.9581.3—

Total equity (KRW Bn)

541.4—272.8

Accumulated deficit (KRW Bn)

——-413.9

Machinery and equipment, book value (KRW Bn)

——152.8

Capital and debt item

Capital and debt itemValue (KRW Bn)DateSource

Share capital before 2026 reduction

99.2

Feb 2026

Dealsite

Share capital after 15:1 reduction

6.6

Apr 2026

Dealsite

Convertible bonds outstanding (16th–18th series)

115.0

Oct 2025

Dealsite

19th-series CB issued

10.0

May 2026

IB Tomato

Loan payable to Aprogen Inc.

53.5

Early 2024

Asia Economy (Mar 2024)

Aprogen Inc. CB holdings in the company

60.0

Sep 2023

Hankyung (Jan 2024)

AP Healthcare finance-lease receivable from the company

19.4

Q2 2024

NewDaily (Sep 2024)

Collateral pledged for parent's borrowings (Osong land and buildings)

81.0

Jun 2026

IB Tomato (9.0 Dec 2025 + 63.0 Apr 2026 + 9.0 Jun 2026)

Financing Event Details

Financing eventDateAmount (KRW Bn)Counterparty

Rights offering (shareholder allotment plus public offering of unsubscribed shares)

Aug 2019

85.7

Public / shareholders

Rights offering (planned; resized from 117.2)

Mar–May 2024

72.4

Shareholders; Korea Investment & Securities as underwriter

Third-party placement

Jul 2024

60.0

Aprogen Inc.

16th-series CB (private)

Jul 2024

40.0—

17th-series CB

Mar 2025

65.0—

18th-series CB (3% coupon, matures 24 Oct 2030, conversion price KRW 605 pre-consolidation)

Oct 2025

15.0

APTN (affiliate)

Third-party placement

Apr 2026

2.0

Aprogen Inc.

19th-series CB

May 2026

10.0

Aprogen Inc.

Third-party placement

Jul 2026

2.0

Aprogen Inc.

Third-party placement (12,706,481 shares at KRW 1,574)

Sep 2026

20.0

Aprogen Inc.

“—” = not publicly disclosed.

Financial Analysis

RatioValueDate / source

ROE (%)

-35.04

Sep 2026, MarketInOut

ROE (%)

-40.3

Oct 2026, Butler

ROE (%)

-50.55

Aug 2026, StockHub

ROA (%)

-13.43

Sep 2026, MarketInOut

ROIC (%)

-7.36

Sep 2026, MarketInOut

Pre-tax margin (%)

-85

Sep 2026, MarketInOut

Debt / equity (x)

1.09

Sep 2026, MarketInOut

Altman Z-score

-1.19

Sep 2026, MarketInOut

Piotroski F-score

4 of 9

Sep 2026, MarketInOut

Beneish M-score

-2.5

Sep 2026, MarketInOut

Price / book (x)

0.22

Oct 2026, Butler

Balance Sheet (FY2021–FY2025)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

26.378.3150.6150.1118.0

Gross profit (KRW Bn)

-0.46.235.834.9—

Operating income (KRW Bn)

-94.6-119.3-88.9-86.8-95.6

Pre-tax income (KRW Bn)

-119.3-115.6-95.2-98.7—

Net income (KRW Bn)

-119.2-116.1-97.3-100.4—

Total assets (KRW Bn)

477.6599.9594.4609.9—

Cash and equivalents (KRW Bn)

15.943.135.737.1—

Borrowings (KRW Bn)

429.781.0101.0100.3—

Net debt (KRW Bn)

413.837.965.363.1—

Total equity (KRW Bn)

-0.8461.0417.7440.1—

Region revenue (KRW Bn)

Region revenue (KRW Bn)FY2023FY2024FY2025

Total

87.467.473.2

Share Price & Returns

PeriodReturn (%)As-of date / source

1 week

-4.42

9 Sep 2026, MarketInOut

1 month

-21.46

9 Sep 2026, MarketInOut

6 months

-76.62

9 Sep 2026, MarketInOut

1 year

-81.55

9 Sep 2026, MarketInOut

Year-to-date

-51.5

15 May 2026, SK Securities (Quantiwise)

1 year

-62.2

15 May 2026, SK Securities (Quantiwise)

3 years / 5 years

—

Not computed in sources reviewed; complicated by 2024 and 2026 consolidations

Share Count (millions)

MetricJan2024Oct2025Apr2026Sep2026Oct2026

Shares outstanding (millions)

665198.413.216.329.0

Valuation Multiples

MultipleAprogen BiologicsNotes

EV/EBITDA (x)

-7.25

MarketInOut, Sep 2026; negative EBITDA

EV/Sales (x)

3.32

MarketInOut, Sep 2026; before the September placement

P/B (x)

0.22

Butler, Oct 2026

Capital Instruments

InstrumentAmount (KRW Bn)CouponMaturityHolder

16th-series CB

40.0———

17th-series CB

65.0—

Not disclosed; to be refinanced in part by 18th series

—

18th-series CB

15.03%

24 Oct 2030

APTN

19th-series CB

10.0——

Aprogen Inc.

Loan from Aprogen Inc.

53.5 (early 2024)

——

Aprogen Inc.

“—” = not publicly disclosed.

Analyst Conclusions

Management guidance and consensus

Aprogen Biologics guidance: none formally issued.

Group IR (June 2025): turnaround expected around 2027, driven by CDMO contracts, biosimilar licensing and novel drugs.

Consensus: none (no coverage).

Bull case

  1. Regulatory catalyst. With FDA and EMA indicating that AP063 can be approved without confirmatory Phase 3, PPQ batches at Osong in 2026–2027 would convert the plant from idle to productive. Each AP063 batch is claimed at 92 kg.

  2. Asset value versus market value. Market capitalisation of about KRW 42 bn compares with equity of KRW 272.8 bn (P/B 0.22) and a plant that cost about KRW 600 bn. Any contract that monetises the plant could re-rate the shares.

  3. Diversified earnings floor. The pharmaceutical segment (profitable in Q1 2026) and the semiconductor segment (KRW 2.25 bn H1 operating profit) give a revenue base of about KRW 86 bn TTM that cushions bio losses.

Bear case

  1. Funding treadmill. Losses of about KRW 60 bn a year at operating level and KRW 105–168 bn at net level are being funded by repeated parent and affiliate placements and CBs. The parent itself lost KRW 95.6 bn at operating level in FY2025.

  2. Minority-shareholder dilution and governance. Two consolidations (2024 and 2026), a placement equal to 78% of the share count to the parent for an undetermined acquisition, and about KRW 81 bn of collateral for the parent's debt all signal that minority interests rank behind group needs.

  3. Delisting and impairment. The KRX warning (October 2026) and a possible write-down of the KRW 152.8 bn machinery balance at year-end 2026 could trigger administrative-issue designation and further equity erosion before any biosimilar revenue arrives.

Key catalysts and monitorables (next 12 months)

  • Whether KRX designates the stock an administrative issue after the October 2026 warning, and whether the new shares listed in October lift market capitalisation above the threshold.

  • Identity of the target for the September 2026 KRW 20 bn acquisition funding, and the identity and repayment of the KRW 29.1 bn 아인스팩 loan.

  • AP063 PPQ start at Osong and US BLA / EU MAA submission dates.

  • First commercial CDMO contract announcement (value, client, duration).

  • FY2026 year-end impairment testing of Osong assets.

  • Release or extension of the Osong collateral pledged for Aprogen Inc.

  • Conversion activity on outstanding CBs and any new CB or placement.

  • Disclosure of the semiconductor segment's legal structure and outlook.

Analyst verdict

Aprogen Biologics is best understood as an option on the Aprogen group's biosimilar strategy, carried by a balance sheet that is being steadily drawn down. The underlying asset is real. Osong is a modern, certified, fully integrated antibody plant, and its perfusion process has produced clinical-scale batches at yields well above conventional fed-batch norms. The regulatory environment has also moved in the group's favour. FDA and EMA feedback that AP063 may not need a confirmatory Phase 3 is a meaningful de-risking step, and it shortens the path to commercial volumes.

The financial record, however, shows a business that has not yet earned its cost of capital at any point since the December 2022 merger. Operating losses have run at KRW 52.8–60.4 bn a year. Net losses reached KRW 168.3 bn in FY2025. Equity halved in about two and a half years, and the plant produced nothing in Q1 2026. The company has filled the gap through capital actions that dilute or subordinate outside shareholders. These include two share consolidations, repeated placements to the parent, CBs placed with affiliates, collateral pledged for the parent's debt, and a 78% share issuance for an acquisition the company itself says is undetermined. Because the parent is itself loss-making, the support network is circular rather than independent.

For investors, three conditions would need to hold for value to accrue to minority holders: AP063 PPQ and filings proceed on schedule; a bona fide third-party CDMO contract is signed; and governance practices around related-party funding improve. None is assured. Until at least two are visible, the shares should be treated as a high-risk, event-driven position, with listing-maintenance and dilution as the dominant near-term risks. On current evidence, the risk-reward is unfavourable for minority shareholders, and position sizing should reflect the possibility of administrative-issue designation and further capital actions in 2026–2027.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / backgroundEducation

Kim Jeong-chool (김정출)

Co-CEO

Co-CEO since at least March 2023 (Asia Economy); also listed as CEO by Simply Wall St

—

Kim Jae-seob (김재섭)

Co-CEO; also CEO of Aprogen Inc. and inside director of G-Base

Founder of Aprogen (2000); previously associate professor of biological sciences at KAIST, assistant professor at Seoul National University's Institute for Molecular Biology and Genetics, and research assistant professor at the University of Wisconsin; CEO of Schnell Biopharmaceuticals around 2013

PhD, MSc and BSc in Microbiology, Seoul National University

Lee Seung-ho (이승호)

Former co-CEO, head of bio division

——

Na Oh-seong (나오성)

Managing Director, Osong Plant Head

Previously head of fill-finish at Aprogen Biologics; HA/DS team leader at Hanmi Pharmaceutical; culture-team supervisor and fill-finish team lead at Celltrion

MSc Chemistry, POSTECH; BSc Chemistry, Dongguk University

“—” = not publicly disclosed.

Major Shareholders

HolderStake (%)DateSource

Aprogen Inc.

53.77

Mar 2024

Asia Economy

Aprogen Inc.

56.87

31 Mar 2025

Aprogen IR (Jun 2025)

Aprogen Inc. ("Aprogen Medicines Inc.")

64.19

2026 (9,202,202 shares per Investing.com)

Investing.com

Undisclosed buyer (acquired from Aprogen Inc.)

6.87

Jul 2024

MarketScreener

APTN (affiliate)

CB holder, KRW 15 bn 18th series; equity stake not disclosed

Oct 2025

Dealsite

Treasury shares

0.53

Oct 2026

Butler

Free float

23.462025

MarketScreener

Competitive Landscape

Market Share by Competitor

CompanyShare of global CDMO market 2023 (%)

Lonza

25.6

WuXi Biologics

12.1

Catalent

10.1

Samsung Biologics

9.9

Fujifilm

6.8

Boehringer Ingelheim

5.9

AGC Biologics

4.4

Others

25.2

Key Competitors

CompanyInstalled volume (thousand L)Process

Samsung Biologics

604

Fed-batch (Plants 1–4)

Celltrion

250

Fed-batch (Plants 1–3)

Aprogen Biologics (actual)

10.5

Perfusion

Aprogen Biologics (company-claimed fed-batch equivalent)

360

Conversion claimed by Aprogen

Peer Comparison FY2025

MetricAprogen BiologicsCelltrionSamsung BiologicsPrestige BioLogics

Revenue (KRW Bn)

73.24,162.54,557.012.5

Revenue growth YoY (%)

8.617.030.3—

Operating income (KRW Bn)

-60.41,168.52,069.2—

Operating margin (%)

-82.528.145.4—

Recent Developments

Not identified in sources reviewed: * layoffs, product launches, contract wins, and litigation events. The TheVC headcount series (146 in June 2026, down 6% month-on-month) suggests ongoing attrition.

Company Snapshot

$51.5M

Revenue

262

Employees

1960

Founded

SWOT Analysis

Strengths

  • Large, modern biologics asset. The Osong plant (completed January 2020; GFA 52,247 m²; about KRW 600 bn invested per Aprogen IR) offers integrated drug-substance and drug-product capability, including PFS capacity of 80 million units a year.
  • Demonstrated perfusion productivity. The AP096 pre-approval run in November 2024 harvested 201.5 kg of antibody from a single 2,000 L working-volume vessel, averaging about 8 kg/day (Aprogen IR).
  • Regulatory credentials. The plant holds kGMP certification and, from June 2024, MFDS approval as a specialised biopharmaceutical CMO (Hankyung, Jan 2025).
  • Captive pipeline with regulatory de-risking. AP063 received FDA pre-BLA feedback (May 2026) and EMA scientific advice that confirmatory Phase 3 is not required. The remaining steps are PPQ and filing (Fnnews, May 2026).
  • Established domestic pharma franchise. The 65-year operating history (since 1960) gives a domestic prescription-drug base. The segment was profitable in Q1 2026 (KRW 1.8 bn operating profit) and provided 62% of Q2 2026 revenue.
  • Committed controlling shareholder. Aprogen Inc. has repeatedly recapitalised the company: KRW 60 bn in July 2024, KRW 10 bn CB in May 2026, and KRW 20 bn in September 2026 (IB Tomato).

Weaknesses

  • Idle core asset. Osong recorded 0 L of biologic output in Q1 2026, while Q1 machinery depreciation was about KRW 3.1 bn (IB Tomato, May 2026).
  • Structural losses. Operating losses were KRW 57.5 bn (FY2023), KRW 52.8 bn (FY2024) and KRW 60.4 bn (FY2025), with operating margins of –65.8% to –82.5% (Butler).
  • Equity erosion. Equity fell from KRW 541.4 bn (September 2023) to KRW 272.8 bn (Q1 2026), and the accumulated deficit reached KRW 413.9 bn.
  • Encumbered real estate. About KRW 81 bn of Osong land and buildings has been pledged as collateral for the parent's borrowings (December 2025, April 2026 and June 2026).
  • Weak market-facing governance. The company reversed its March 2023 public statement that no capital reduction was planned, with consolidations in 2024 and 2026. Outside directors were absent when the September 2026 related-party placement was approved.
  • Opaque disclosure. There is no English-language reporting, no sell-side coverage (0 reports per StockHub), and no published detail on the origin of the semiconductor segment or on segment history.

Opportunities

  • AP063 approvals. Approval in the US and EU without Phase 3 would bring PPQ and commercial volume to Osong. The group claims capacity of 736 kg a year of AP063, about 40% of global consumption (Aprogen IR).
  • Pipeline backfill. AP096 (adalimumab) and AP056 (rituximab) clinical material is already produced, so they can follow AP063 under the same simplified regulatory pathway (Aprogen IR, Jun 2025).
  • Third-party CDMO demand. The Biosecure Act could redirect business. Prospective clients have audited Osong (European "Company O") and one trial run is completed (Hankyung, Jan 2025).
  • Fill-finish as a near-term revenue source. The plant can make lyophilised vials, liquid vials, PFS and auto-injectors, and drug-product work can be sold separately from drug substance.
  • Group novel-drug supply. AP209 (osteoarthritis; Korean trial approved for 46 patients), PMC-309, and the Parkinson's programme would all require clinical manufacturing.
  • Semiconductor diversification. The semiconductor segment provided 33% of Q2 2026 revenue and KRW 2.25 bn of H1 operating profit, which can partly offset losses.

Threats

  • Listing-maintenance risk. KRX issued an administrative-issue warning on 6 October 2026 after 25 trading days with market capitalisation below KRW 30 bn (Medical Times, Oct 2026).
  • Dilution overhang. After the 18th-series CB, potential conversion shares equalled 95.6% of outstanding shares (October 2025). Further CBs and placements followed in 2026 (Dealsite; IB Tomato).
  • Impairment. The KRW 152.8 bn machinery balance may require write-downs if the plant stays idle (IB Tomato, May 2026).
  • Parent credit risk. Aprogen Inc. reported an FY2025 operating loss of KRW 95.6 bn on KRW 118.0 bn of revenue, and the subsidiary's collateral backs the parent's debts.
  • Competitive scale. Samsung Biologics (FY2025 operating income KRW 2,069.2 bn) and Celltrion (KRW 1,168.5 bn) dominate the Korean biologics ecosystem and are expanding US capacity.
  • Biosimilar price erosion. Group materials note trastuzumab prices nearing a floor, which narrows the margin advantage the low-cost strategy depends on (Aprogen IR).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
14 May 2025Q1 2025 quarterly report filedRoutine
Jun 2025Aprogen IR deck shows Aprogen Inc. at 56.87% and Aprogen Biologics total assets of KRW 581.3 bn (Mar 2025); 13-project CDMO strategy; turnaround targeted around 2027Baseline for strategy and ownership
Aug 2025Aprogen Inc. licenses PMC-309 (anti-VISTA) from PharmAbcineAdds potential future manufacturing work for Osong
13 Aug 2025H1 2025 report filedRoutine
22–23 Sep 2025Dealsite reports CDMO contract talks with global pharma and Osong expansion plansSentiment; no contract disclosed
16 Oct 2025Board approves KRW 15 bn 18th-series CB to affiliate APTN (conversion KRW 605; potential dilution 11.11%; total CB balance KRW 115 bn; potential conversion shares equal to 95.6% of outstanding shares)Heavy dilution overhang; related-party funding
23 Oct 2025KRW 15 bn received from APTNLiquidity
5 Nov 2025Aprogen announces three-pillar strategy (biosimilars, new drugs, hybrid CMO)Strategic messaging
6 Nov 2025AP063 programme restructured toward quality and PK; about KRW 130 bn of cost savings claimedFaster path to Osong utilisation if approved
13 Nov 2025Q3 2025 report filedRoutine
Dec 2025KRW 9 bn of collateral pledged for Aprogen Inc. borrowingsContingent liability
23 Feb 202615:1 capital reduction by consolidation decided (record date 14 April; AGM 30 March)Deficit relief; KRX penny-stock rule response
12 Mar 2026Press reports that the stock fell below pre-announcement levels after a brief reboundMarket scepticism
20 Mar 2026FY2025 annual report filed (revenue KRW 73.2 bn; operating loss KRW 60.4 bn; net loss KRW 168.3 bn)Losses widen
30 Mar 2026AGM scheduled to approve capital reductionGovernance event
13 Apr 2026Rights-offering (third-party) decision disclosedSmall capital raise
14 Apr 2026Capital-reduction record date (198.4 million shares become 13.2 million)Share-count reset
Apr 2026KRW 63 bn of Osong land and buildings pledged for the parent's borrowingsMaterial encumbrance
8 May 2026Aprogen reports FDA pre-BLA feedback that AP063 needs no confirmatory Phase 3Key regulatory de-risking
14 May 2026Q1 2026 report; stock rises 16.73% intraday to KRW 5,720 on EMA and OA-drug newsPeak sentiment of 2026
21 May 2026KRW 10 bn 19th-series CB decidedFurther dilution overhang
27–29 May 2026IB Tomato: Osong produced 0 L in Q1 2026; accumulated deficit KRW 413.9 bn; impairment risk on KRW 152.8 bn of machineryExposes the cost of the idle plant
Jun 2026Additional KRW 9 bn of collateral pledged for the parentEncumbrance rises to about KRW 81 bn
Jun–Jul 2026Aprogen Inc. receives Korean approval for the AP209 osteoarthritis trial (46 patients)Potential future Osong clinical supply
Jul 2026KRW 2 bn third-party placement to Aprogen Inc.Related-party funding
Aug 2026AP209 IRB submitted at Kyung Hee University HospitalPipeline progress (parent)
13 Aug 2026H1 2026 report: revenue KRW 44.7 bn; operating loss KRW 31.1 bn; semiconductor segment the only profitable unitLoss run-rate unchanged
4–7 Sep 2026KRW 20 bn placement to Aprogen at KRW 1,574 (12.7 million shares, 78% of pre-issue shares) for an undetermined acquisition; parent issues KRW 20 bn CB the same dayGovernance controversy; minority dilution
11 Sep 2026Amended filing and substantial-holding reportDisclosure update
23 Sep 2026Placement result filed; KRW 29.1 bn one-year loan to 아인스팩 at 4.6%Use of funds outside core operations
2 Oct 2026New shares scheduled to listShare count rises to about 28.97 million
6 Oct 2026KRX "concern over administrative-issue designation" notice (market cap below KRW 30 bn for 25 trading days)Listing-maintenance risk
8 Oct 2026Collateral-provision decision for another party; substantial-holding report–
Oct 2026IB Tomato reports N2Tech-linked fund buying Aprogen and Aprogen Biologics CBs; group affiliates described as dependent on N2Tech fundingIntra-group funding scrutiny

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Total company fell from KRW 87,400 Mn in FY2023 to KRW 73,200 Mn in FY2025.
Aprogen pharmaceuticals,Inc. — Revenue by Segment
Series (KRW Mn)FY2023FY2024FY2025
Total company87,40067,40073,200

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Butler — 에이프로젠바이오로직스 (003060) financials and filings (butler.works)
  2. IB Tomato / NewsTomato (9 Sep 2026), 200억 placement (newstomato.com)
  3. IB Tomato / NewsTomato (29 May 2026), Osong zero output (newstomato.com)
  4. IB Tomato / NewsTomato (Oct 2026), N2Tech funding (newstomato.com)
  5. IB Tomato / NewsTomato (Jul 2024), placement and CB (newstomato.com)
  6. Aprogen Inc. IR presentation (Jun 2025) (file.alphasquare.co.kr)
  7. Aprogen Inc. IR presentation (Dec 2024) (file.alphasquare.co.kr)
  8. Dealsite (23 Feb 2026), 15:1 capital reduction (dealsite.co.kr)
  9. Dealsite (16 Oct 2025), 18th-series CB (dealsite.co.kr)
  10. Dealsite (23 Sep 2026), 아인스팩 loan (dealsite.co.kr)
  11. Dealsite (May 2025), Aprogen holding-company structure (dealsite.co.kr)
  12. Dealsite (Sep 2025), CDMO capacity (dealsite.co.kr)
  13. Dealsite (Nov 2025), Aprogen strategy (dealsite.co.kr)
  14. Dealsite (May 2026), Prestige BioLogics (dealsite.co.kr)
  15. Asia Economy (Mar 2024), rights offering (core.asiae.co.kr)
  16. Asia Economy (Mar 2023), CDMO and no-reduction statement (core.asiae.co.kr)
  17. Asia Economy (Apr 2020), group restructuring (core.asiae.co.kr)
  18. Asia Economy (Jul 2023), AP063 Phase 3 (core.asiae.co.kr)
  19. Asia Economy (Jun 2020), raloxifene (asiae.co.kr)
  20. Hankyung (Jan 2024), rights offering (hankyung.com)
  21. Hankyung (Jan 2025), CDMO (hankyung.com)
  22. Hankyung (Jan 2025), CDMO orders (hankyung.com)
  23. Edaily via Daum (Mar 2024), Biosecure Act (v.daum.net)
  24. Fnnews (8 May 2026), FDA pre-BLA AP063 (fnnews.com)
  25. Finance Scope (Nov 2025), AP063 redesign (finance-scope.com)
  26. Finance Scope (Oct 2024), FDA BPD meeting (finance-scope.com)
  27. Medical Times (Oct 2026), KRX warning (medicaltimes.com)
  28. Medical Times (Mar 2026), penny-stock measures (medicaltimes.com)
  29. Medical Times (Mar 2016), Nichi-Iko AP056 licence (medicaltimes.com)
  30. Medical Times (Nov 2011), Seongnam plant (medicaltimes.com)
  31. Daily Pharm (Mar 2026), consolidations (dailypharm.com)
  32. Bizwatch (Mar 2026) (news.bizwatch.co.kr)
  33. JKN (May 2026), share move (news.jkn.co.kr)
  34. eToday (Feb 2010), Schnell history (etoday.co.kr)
  35. eToday (Jan 2026), Samsung Biologics and Celltrion (etoday.co.kr)
  36. NewsTomato (Jan 2013), SDR-grafting patent (newstomato.com)
  37. NewDaily (Sep 2024), AP Healthcare (biz.newdaily.co.kr)
  38. Biospectator (Feb 2026), Celltrion FY2025 (biospectator.com)
  39. SK Securities weekly (May 2026) (stock.pstatic.net)
  40. MarketInOut (003060) (marketinout.com)
  41. Investing.com (003060) (ca.investing.com)
  42. Paasa (003060) (paasa.com)
  43. MarketScreener (Aprogen Biologics) (marketscreener.com)
  44. Simply Wall St (A003060) (simplywall.st)
  45. StockHub (003060) (stockhub.kr)
  46. TheVC (Aprogen Biologics) (thevc.kr)
  47. TheVC (Nichi-Iko) (thevc.kr)
  48. Valueline (007460) (valueline.co.kr)
  49. Catch (recruitment and company data) (catch.co.kr)
  50. etfshopping (earnings dates) (etfshopping.com)
  51. Dealroom (Aprogen) (app.dealroom.co)
  52. CB Insights (Aprogen) (cbinsights.com)
  53. PatSnap (Aprogen Pharmaceuticals) (discovery.patsnap.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.